Related Experiment Video
Updated: Oct 28, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
New and Emerging Drug Therapy in Primary Open-Angle and Normal-Tension Glaucoma: Pharmacology, Neuroprotection and
Stephanie Mroczkowska1, Leanne Smewing1, Doina Gherghel2
1Eye and Vision Research Group, Faculty of Health, University of Plymouth, Plymouth PL4 6AB, UK.
Abstract:
Glaucoma is a group of progressive optic neuropathies characterized by retinal ganglion cell (RGC) loss, optic nerve head damage and corresponding visual-field loss. Intraocular pressure (IOP) is the principal modifiable risk factor, and lowering IOP remains the only treatment approach that has been shown in randomized clinical trials to slow glaucomatous progression, including in normal-tension glaucoma (NTG). However, IOP reduction does not eliminate progression in all patients, indicating that susceptibility to pressure-related damage is heterogeneous and that additional biological mechanisms are relevant. This review examines current and emerging pharmacological strategies for IOP lowering, approaches intended to protect RGCs independently of IOP, and the methodological problem of demonstrating neuroprotection in clinical trials.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
